{"disease":{"id":"psoriatic-arthritis","name":"Psoriatic Arthritis","therapeutic_area":"Immunology & Inflammation","data":{"aiSummary":"The treatment landscape for psoriatic arthritis has evolved significantly, with a shift towards targeted therapies. TNF inhibitors and IL-17 inhibitors are well-established, offering effective control of joint and skin symptoms. Apremilast, an oral PDE4 inhibitor, provides an alternative for milder cases. Recent advances include the approval of new biologics and the ongoing development of novel agents targeting various inflammatory pathways. The pipeline includes several promising therapies, such as IL-23 inhibitors and TYK2 inhibitors, which may offer improved efficacy and safety profiles. The focus remains on early and aggressive treatment to prevent joint damage and improve patient outcomes.","drug_count":11,"description":"Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by a combination of arthritis, psoriasis, and enthesitis. It is a seronegative spondyloarthritis that can cause joint damage, pain, swelling, and stiffness. The pathophysiology involves immune dysregulation, genetic predisposition, and environmental factors, leading to inflammation in the joints, skin, and other tissues. Current treatment focuses on controlling inflammation, relieving symptoms, and preventing joint damage.","subtype_count":16},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.960Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":23,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":84,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"risankizumab","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Skyrizi","generic_name":"RISANKIZUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Interleukin-23 subunit alpha","drug_class":"Interleukin-23 Antagonist [EPC]","quality_score":60,"revenue":"8600","mechanism":"Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in pediatric patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"secukinumab","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosentyx","generic_name":"secukinumab","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Interleukin-17A (IL-17A)","drug_class":"IL-17A antagonist","quality_score":89,"revenue":"3900","mechanism":"Secukinumab selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor."},{"drug_id":"ixekizumab","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taltz","generic_name":"ixekizumab","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Interleukin 17A (IL-17A) cytokine","drug_class":"Interleukin-17A antagonist","quality_score":82,"revenue":"2700","mechanism":"Humanized IgG4 monoclonal antibody that selectively binds IL-17A cytokine and inhibits its interaction with IL-17 receptor."},{"drug_id":"tofacitinib","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"tofacitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":97,"revenue":"1800","mechanism":"Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs."},{"drug_id":"tofacitinib","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"tofacitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":97,"revenue":"1800","mechanism":"Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs."},{"drug_id":"certolizumab-pegol","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cimzia","generic_name":"CERTOLIZUMAB PEGOL","company_name":"UCB","drug_phase":"marketed","molecular_target":"TNFα","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":68,"revenue":"1600","mechanism":"Certolizumab pegol binds to and neutralizes human TNFα, reducing inflammation without causing antibody-dependent cell-mediated cytotoxicity."},{"drug_id":"in-open-label-phase-treatment-with-tofacitinib","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"In open-label phase: treatment with tofacitinib","generic_name":"in-open-label-phase-treatment-with-tofacitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2)","drug_class":"Janus kinase inhibitor","quality_score":45,"revenue":"1087","mechanism":""},{"drug_id":"infliximab-infliximab-biosimilar-3","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Infliximab [infliximab biosimilar 3]","generic_name":"infliximab-infliximab-biosimilar-3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor-alpha (TNF-alpha)","drug_class":"monoclonal antibody","quality_score":67,"revenue":"646","mechanism":"Infliximab biosimilar 3 is a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha) to treat inflammatory conditions."},{"drug_id":"deucravacitinib","indication_name":"Active psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sotyktu","generic_name":"DEUCRAVACITINIB","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Non-receptor tyrosine-protein kinase TYK2","drug_class":"Tyrosine Kinase 2 Inhibitor [EPC]","quality_score":69,"revenue":"291","mechanism":"Sotyktu works by blocking the TYK2 enzyme, which is involved in the inflammatory response and contributes to the development of psoriasis."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis and atopic dermatitis and hidradenitis suppurativa and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Psoriatic Arthritis with Distal Interphalangeal Involvement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tasocitinib","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasocitinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"tasocitinib","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasocitinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"adalimumab","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":67,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Psoriatic Arthritis with Distal Interphalangeal Involvement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis with Distal Interphalangeal Involvement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tnf-inhibitor","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TNF Inhibitor","generic_name":"tnf-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"TNF-alpha","drug_class":"Monoclonal Antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Active psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe atopic dermatitis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe plaque psoriasis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and hidradenitis suppurativa","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe hidradenitis suppurativa and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ulcerative colitis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe ankylosing spondylitis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe non-radiographic axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and non-radiographic axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and axial spondyloarthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-50-mg-sc-q4w","indication_name":"Moderate to severe axial spondyloarthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 50 mg SC Q4W","generic_name":"chronic-pf-06480605-50-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"tofacitinib-xeljanz","indication_name":"Psoriatic Arthritis (PsA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofacitinib (Xeljanz)","generic_name":"tofacitinib-xeljanz","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK3","drug_class":"Janus Kinase Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-adbm","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"taltz","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taltz","company_name":"Yale University","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"induction-pf-06480605-150-mg-sc-q4w","indication_name":"Psoriatic Arthritis and Ankylosing Spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 150 mg SC Q4W","generic_name":"induction-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK pathway","drug_class":"JAK inhibitor","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks."},{"drug_id":"anti-beta-interferon-pf-06823859","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anti-Beta Interferon (PF-06823859)","generic_name":"anti-beta-interferon-pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta interferon","drug_class":"Monoclonal antibody","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Active psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe rheumatoid arthritis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and rheumatoid arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ankylosing spondylitis and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease and rheumatoid arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Active psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis and ankylosing spondylitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis and Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis and psoriatic arthritis and ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-150-mg-sc-q4w","indication_name":"Moderate to severe psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis, and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 150 mg SC Q4W","generic_name":"chronic-pf-06480605-150-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK2 enzymes","drug_class":"Janus kinase inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"intra-articular-corticosteroid-injections","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intra-articular corticosteroid injections","generic_name":"intra-articular-corticosteroid-injections","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"xeljanz-xr","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"Tofacitinib Citrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":72,"revenue":null,"mechanism":"Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation."},{"drug_id":"xeljanz-xr","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"Tofacitinib Citrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":72,"revenue":null,"mechanism":"Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation."},{"drug_id":"methotrexate","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"methotrexat","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cimzia","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cimzia","company_name":"University of Washington","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humira","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tofa","indication_name":"Juvenile psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOFA","company_name":"","drug_phase":"marketed","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tofa","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOFA","company_name":"","drug_phase":"marketed","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ustekinumab-aekn","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SELARSDI","generic_name":"USTEKINUMAB-AEKN","company_name":"ALVOTECH USA INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-aqvh","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"YUSIMRY","generic_name":"ADALIMUMAB-AQVH","company_name":"COHERUS BIOSCIENCES INC","drug_phase":"marketed","molecular_target":"","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"bimekizumab-bkzx","indication_name":"Active psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BIMZELX","generic_name":"BIMEKIZUMAB-BKZX","company_name":"UCB INC","drug_phase":"marketed","molecular_target":"Interleukin-17A, Interleukin-17F, Interleukin-17AF","drug_class":"","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"ustekinumab-auub","indication_name":"Active Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"WEZLANA","generic_name":"USTEKINUMAB-AUUB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Interleukin-12 Antagonist [EPC]","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"drug-abatacept","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"drug-abatacept","indication_name":"Psoriatic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Drug: \"Abatacept\"","company_name":"Shinshu University","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"cosentyx","indication_name":"Psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cosentyx","company_name":"Janssen Research & Development, LLC","drug_phase":"marketed","molecular_target":"Interleukin-17A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Active psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe psoriatic arthritis and axial involvement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Active psoriatic arthritis and axial involvement","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."},{"drug_id":"induction-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe Crohn's disease and perianal disease and fistulizing disease and axial involvement and psoriatic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Induction- PF-06480605 450 mg SC Q4W","generic_name":"induction-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-17 receptor","drug_class":"small molecule","quality_score":59,"revenue":null,"mechanism":"PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions."}],"pipeline":[],"offLabel":[],"totalMarketed":117,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03835780","title":"The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":266890,"lead_sponsor_name":"Momentum Data","has_results":true},{"nct_id":"NCT05413044","title":"A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register","phase":"","overall_status":"COMPLETED","enrollment_count":140706,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT02922192","title":"Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":90360,"lead_sponsor_name":"Biologics & Biosimilars Collective Intelligence Consortium","has_results":false},{"nct_id":"NCT06568029","title":"Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic Disease","phase":"","overall_status":"COMPLETED","enrollment_count":77651,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT05421442","title":"A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database","phase":"","overall_status":"COMPLETED","enrollment_count":38396,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT05858528","title":"HIPPOCRATES Prospective Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04110522","title":"Psoriatic Arthritis D2P Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":18000,"lead_sponsor_name":"Jessica Walsh","has_results":false},{"nct_id":"NCT01965132","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT06766552","title":"A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT03496831","title":"Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":7500,"lead_sponsor_name":"Simon Krabbe","has_results":false},{"nct_id":"NCT01078558","title":"A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )","phase":"","overall_status":"COMPLETED","enrollment_count":5940,"lead_sponsor_name":"AbbVie (prior sponsor, Abbott)","has_results":true},{"nct_id":"NCT04190758","title":"GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":5100,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT03470688","title":"Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Opal Rheumatology Ltd.","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT04655612","title":"Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04614831","title":"A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":4978,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06714461","title":"A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04541810","title":"A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":2369,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04433442","title":"Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":2324,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT04798625","title":"Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Diakonhjemmet Hospital","has_results":false},{"nct_id":"NCT05039216","title":"Biobank for Inflammatory Chronic Diseases and Osteoporosis","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital, Toulouse","has_results":false},{"nct_id":"NCT03104400","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1705,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02486302","title":"A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.","phase":"","overall_status":"COMPLETED","enrollment_count":1534,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02925338","title":"National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life","phase":"","overall_status":"COMPLETED","enrollment_count":1431,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07286058","title":"Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1182,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06172426","title":"Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK Registry","phase":"","overall_status":"COMPLETED","enrollment_count":1171,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04009499","title":"A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1131,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT06671483","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1088,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05190484","title":"bIosimilar of aDalimumab, an European evAluation","phase":"","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT02984020","title":"Korean Post-marketing Surveillance for Xeljanz","phase":"","overall_status":"COMPLETED","enrollment_count":1041,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07041112","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Juan Ruano Ruiz","has_results":false},{"nct_id":"NCT06059430","title":"Cohort Project of Patients With Inflammatory Rheumatism","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nice","has_results":false},{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT06802848","title":"Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Chongqing Genrix Biopharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT05621369","title":"Psorcast Mobile Study","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Sage Bionetworks","has_results":false},{"nct_id":"NCT02404350","title":"Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":997,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02627768","title":"A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis","phase":"","overall_status":"COMPLETED","enrollment_count":991,"lead_sponsor_name":"Janssen Pharmaceutica N.V., Belgium","has_results":false},{"nct_id":"NCT03675308","title":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":964,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT02745080","title":"Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":853,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03895203","title":"A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":852,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT02376790","title":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":851,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05080218","title":"COVID-19 VaccinE Response in Rheumatology Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":841,"lead_sponsor_name":"Jeffrey Curtis","has_results":false},{"nct_id":"NCT04347798","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","phase":"","overall_status":"COMPLETED","enrollment_count":773,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT05677542","title":"Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence Study","phase":"","overall_status":"COMPLETED","enrollment_count":758,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05051943","title":"A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response","phase":"","overall_status":"COMPLETED","enrollment_count":754,"lead_sponsor_name":"Fresenius Kabi","has_results":false},{"nct_id":"NCT00245960","title":"Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":752,"lead_sponsor_name":"Wyeth is now a wholly owned subsidiary of Pfizer","has_results":true},{"nct_id":"NCT04908189","title":"A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":729,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true}],"total":50},"guidelines":[{"drug_id":"xeljanz","guideline_body":"FDA label","recommendation":"XELJANZ (tablets and oral solution) is indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ XR (extended-release tablets) is indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"xeljanz-xr","guideline_body":"FDA label","recommendation":"XELJANZ (tablets and oral solution) is indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ XR (extended-release tablets) is indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"xeljanz-xr","guideline_body":"FDA label","recommendation":"XELJANZ (tablets and oral solution) is indicated for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"adalimumab","guideline_body":"FDA label","recommendation":"Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.","line_of_therapy":"1L|2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"inflectra","guideline_body":"FDA label","recommendation":"reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"ixekizumab","guideline_body":"FDA label","recommendation":"TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"ixekizumab","guideline_body":"FDA label","recommendation":"TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"ixekizumab","guideline_body":"FDA label","recommendation":"TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"abrilada","guideline_body":"FDA label","recommendation":"Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.","line_of_therapy":"1L|2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"secukinumab","guideline_body":"FDA label","recommendation":"Secukinumab is indicated for the treatment of active psoriatic arthritis in adults and pediatric patients 2 years of age and older.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"secukinumab","guideline_body":"FDA label","recommendation":"Secukinumab is indicated for the treatment of active enthesitis-related arthritis in pediatric patients 4 years of age and older.","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"tofacitinib","guideline_body":"FDA label","recommendation":"XELJANZ (tablets and oral solution) is indicated for the treatment of adult and pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers. XELJANZ XR (extended-release tablets) is indicated for the treatment of adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"tofacitinib","guideline_body":"FDA label","recommendation":"XELJANZ (tablets and oral solution) is indicated for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to one or more TNF blockers.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"upadacitinib","guideline_body":"FDA label","recommendation":"RINVOQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"upadacitinib","guideline_body":"FDA label","recommendation":"RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}